Pesquisando por: "DNA and sequencing" - Fotoarena - Agência de fotojornalismo

RC2816AF63PW U.S. Congressman Mike Gallagher (R-WI) Chariman of the House Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party, and Ranking Member Raja Krsihnamoorthi (D-IL) listen as Ginkgo Bioworks CEO Dr. Jason Kelly speaks at his DNA sequencing facility in Boston, Massachusetts, U.S., February 12, 2024. REUTERS/Reba Saldanha

RC2816AMYW01 U.S. Congressman Mike Gallagher (R-WI), and chariman of the House Select Committee on the Chinese Communist Party listens as Ginkgo Bioworks founder Tom Knight speaks at his DNA sequencing facility in Boston, Massachusetts, U.S., February 12, 2024. REUTERS/Reba Saldanha

RC2TFR9ZULN7 Chemicals that measure the amount of SARS-CoV-2 DNA before sequencing are pictured at the Penn Center for Research on Coronavirus and Other Emerging Pathogens at the University of Pennsylvania’s Perelman School of Medicine in Philadelphia, Pennsylvania, U.S., December 16, 2021. REUTERS/Hannah Beier

RC2L7I94PS7I FILE PHOTO: Suresh Chintalapati, an inside sales consultant with Illumina, demonstrates how their bench top DNA sequencing machine Miseq works during a symposium on "The Future of Genomic Medicine" at Scripps Seaside Forum in La Jolla, California March 6, 2014. To match Special Report HEALTH-CORONAVIRUS/BGI REUTERS/Sam Hodgson/File Photo

RC20CF9YH6DL Ester Cerdeira Sabino, a Brazilian scientist working on the coronavirus DNA sequencing, is seen at the Tropical Medicine Institute of the Sao Paulo University Medical School in Sao Paulo, Brazil March 2, 2020. REUTERS/Rahel Patrasso

RC20CF9QLZAK Jacqueline Goes de Jesus and Ester Cerdeira Sabino, Brazilian scientists working on the coronavirus DNA sequencing, work with their students at the Tropical Medicine Institute of the Sao Paulo University Medical School in Sao Paulo, Brazil March 2, 2020. REUTERS/Rahel Patrasso

RC20CF9OJ3NG Jacqueline Goes de Jesus, one of Brazil’s scientists that concluded coronavirus DNA sequencing, insert a tube on a portable device connected to a computer that decode virus DNA at the Tropical Medicine Institute of the Sao Paulo University Medical School in Sao Paulo, Brazil March 2, 2020. REUTERS/Rahel Patrasso

RC20CF9FDOZK A woman works at the Tropical Medicine Institute of the Sao Paulo University Medical School, where Brazil’s scientists are working on the coronavirus DNA sequencing, in Sao Paulo, Brazil March 2, 2020. REUTERS/Rahel Patrasso

RC20CF98PP85 A woman works at the Tropical Medicine Institute of the Sao Paulo University Medical School, where Brazil’s scientists are working on the coronavirus DNA sequencing, in Sao Paulo, Brazil March 2, 2020. REUTERS/Rahel Patrasso

RC2ZBF9WWNHN A scientist points to a computer screen showing a graphic of the coronavirus DNA sequencing at the Tropical Medicine Institute of the Sao Paulo University Medical School in Sao Paulo, Brazil March 2, 2020. REUTERS/Rahel Patrasso

RC2ZBF9L6ET7 Jacqueline Goes de Jesus, one of Brazil’s scientists working on the coronavirus DNA sequencing, holds a test tube at the Tropical Medicine Institute of the Sao Paulo University Medical School in Sao Paulo, Brazil March 2, 2020. REUTERS/Rahel Patrasso

RC2ZBF9IVQVM Jacqueline Goes de Jesus (L) and Ester Cerdeira Sabino (R), Brazilian scientists working on the coronavirus DNA sequencing, prepare to work at the Tropical Medicine Institute of the Sao Paulo University Medical School in Sao Paulo, Brazil March 2, 2020. REUTERS/Rahel Patrasso

RC2ZBF93M7L6 Jacqueline Goes de Jesus (L) and Ester Cerdeira Sabino (R), Brazilian scientists working on the coronavirus DNA sequencing, pose at the Tropical Medicine Institute of the Sao Paulo University Medical School in Sao Paulo, Brazil March 2, 2020. REUTERS/Rahel Patrasso

GF10000092356 Alan Shuldiner (R) and Aris Baras, co-heads of the Regeneron Genetics Center, stand near genetic sequencing machines at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015. To match HEALTH-PRECISIONMEDICINE/ REUTERS/Mike Segar

GF10000092355 A robotic DNA sample automation machine works on DNA samples at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015. To match HEALTH-PRECISIONMEDICINE/ REUTERS/Mike Segar

GF10000092354 A robotic DNA sample automation machine works on DNA samples at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015. To match HEALTH-PRECISIONMEDICINE/ REUTERS/Mike Segar

GF10000092353 Technician Matthew Smith loads a robotic DNA sample automation machine at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015. To match HEALTH-PRECISIONMEDICINE/ REUTERS/Mike Segar

GF10000092352 Technician Mike Lattari (rear) works on a genetic sequencing machine as Alan Shuldiner (R) and Aris Baras, co-heads of the Regeneron Genetics Center, pose for a photo at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015. To match HEALTH-PRECISIONMEDICINE/ REUTERS/Mike Segar

GF10000092351 Technician Mike Lattari prepares a flow cell slide for loading onto a genetic sequencing machine at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015. To match HEALTH-PRECISIONMEDICINE/ REUTERS/Mike Segar

GF10000092350 Technician Mike Lattari prepares a flow cell slide for loading onto a genetic sequencing machine at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015. To match HEALTH-PRECISIONMEDICINE/ REUTERS/Mike Segar

GF10000092349 Technician Matthew Smith loads a robotic DNA sample automation machine at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015. To match HEALTH-PRECISIONMEDICINE/ REUTERS/Mike Segar

GF10000092348 Technician Matthew Smith loads a robotic DNA sample automation machine at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015. To match HEALTH-PRECISIONMEDICINE/ REUTERS/Mike Segar

TM3EA8F14PM01 One of the SMRT cells, that can hold around 150,000 DNA molecules, is used in the DNA sequencing lab in the Monsanto research facility in Chesterfield, Missouri, July 28, 2014. Monsanto says their technology-driven plant breeding process is focused on improving the overall genetics of a crop, using parents with characteristics such as disease tolerance, size or baking qualities. Picture taken July 28, 2014. 15 of 25 Monsanto Stand Alone Picture Package. REUTERS/Tom Gannam (UNITED STATES - Tags: ENVIRONMENT FOOD SCIENCE TECHNOLOGY AGRICULTURE)

TM3EA8F14PC01 SMRT Cell trays are stacked in the DNA sequencing lab in the Monsanto research facility in Chesterfield, Missouri, July 28, 2014. Monsanto says their technology-driven plant breeding process is focused on improving the overall genetics of a crop, using parents with characteristics such as disease tolerance, size or baking qualities. Picture taken July 28, 2014. 14 of 25 Monsanto Stand Alone Picture Package. REUTERS/Tom Gannam (UNITED STATES - Tags: ENVIRONMENT FOOD SCIENCE TECHNOLOGY AGRICULTURE)

GM1EA6J1LG501 Molecular Genetics Technical Specialist Jaime Wendt looks at a slide containing DNA at the Human and Molecular Genetics Center Sequencing Core at the Medical College of Wisconsin in Milwaukee, Wisconsin, May 9, 2014. Once strictly the domain of research labs, gene-sequencing tests increasingly are being used to help understand the genetic causes of rare disease, putting insurance companies in the position of deciding whether to pay the $5,000 to $17,000 for the tests. Genetics experts say that sequencing more than doubles the chances that families get a diagnosis, and saves spending on multiple tests of single genes. Even if no treatment is found, the tests can also end hugely expensive medical odysseys as parents frantically search for the cause of their child's furtive illness. Picture taken May 9, 2014. To match Insight HEALTH-SEQUENCING/REUTERS/Jim Young (UNITED STATES - Tags: SCIENCE TECHNOLOGY HEALTH SOCIETY BUSINESS)

GM1EA370H6D01 Suresh Chintalapati, an inside sales consultant with Illumina, displays a flow cell, the slide on which DNA is sequenced in the Miseq, a their bench top DNA sequencing machine, during a symposium on "The Future of Genomic Medicine" at Scripps Seaside Forum in La Jolla, California March 6, 2014. REUTERS/Sam Hodgson (UNITED STATES - Tags: HEALTH SCIENCE TECHNOLOGY)

GM1EA370H2F01 Suresh Chintalapati, an inside sales consultant with Illumina, demonstrates how their bench top DNA sequencing machine Miseq works during a symposium on "The Future of Genomic Medicine" at Scripps Seaside Forum in La Jolla, California March 6, 2014. To match Analysis GENOMICS-FUTURE/ REUTERS/Sam Hodgson (UNITED STATES - Tags: HEALTH SCIENCE TECHNOLOGY)

GM1E9310LGO01 A sign pointing to the Rebecca and John Moores UCSD Cancer Center DNA Sequencing facility at the University of California San Diego in San Diego, California, February 28, 2013. Looming sequestration cuts are expected to adversely effect scientific research in California. REUTER/Mike Blake (UNITED STATES - Tags: POLITICS EDUCATION SCIENCE TECHNOLOGY HEALTH)

GM1E9310LA601 A sign pointing to the Rebecca and John Moores UCSD Cancer Center DNA Sequencing facility at the University of California San Diego in San Diego, California, February 28, 2013. Looming sequestration cuts are expected to adversely effect scientific research in California. REUTER/Mike Blake (UNITED STATES - Tags: POLITICS EDUCATION SCIENCE TECHNOLOGY HEALTH)

PM1E6411H8Y01 Senior scientist Claude Murat uses liquid nitrogen to extract DNA from a sample of truffle at a INRA laboratory (French National Agronomical Research Institute) in Champenoux near Nancy, April 1, 2010. The INRA research unit, lead by research director Francis Martin, has sequenced the genome of the Perigord black truffle to better understand the symbiosis between trees and fungus, including truffles, to ameliorate it's natural growth. REUTERS/Vincent Kessler (FRANCE - Tags: AGRICULTURE FOOD SCI TECH)

PM1E6411H8J01 Senior scientist Claude Murat looks at DNA fingerprints of truffles at the INRA (French National Agronomical Research Institute) laboratory in Champenoux near Nancy, April 1, 2010. The INRA research unit, lead by research director Francis Martin, has sequenced the genome of the Perigord black truffle to better understand the symbiosis between trees and fungus, including truffles, to ameliorate it's natural growth. REUTERS/Vincent Kessler (FRANCE - Tags: AGRICULTURE FOOD SCI TECH)

PM1E6411GQP01 Senior scientist Claude Murat slices through a truffle sample to prepare it for DNA extraction at a the INRA (French National Agronomical Research Institute) laboratory in Champenoux near Nancy, April 1, 2010. The INRA research unit, lead by research director Francis Martin, has sequenced the genome of the Perigord black truffle to better understand the symbiosis between trees and fungus, including truffles, to ameliorate it's natural growth. REUTERS/Vincent Kessler (FRANCE - Tags: AGRICULTURE FOOD SCI TECH)

PM1E6411GJZ01 Senior scientist Claude Murat uses liquid nitrogen to extract DNA from a sample of truffle at a INRA laboratory (French National Agronomical Research Institute) in Champenoux near Nancy, April 1, 2010. The INRA research unit, lead by research director Francis Martin, has sequenced the genome of the Perigord black truffle to better understand the symbiosis between trees and fungus, including truffles, to ameliorate it's natural growth. REUTERS/Vincent Kessler (FRANCE - Tags: AGRICULTURE FOOD SCI TECH)

PM1E6411GHR01 Senior scientist Claude Murat uses liquid nitrogen to extract DNA from a sample of truffle at a INRA laboratory (French National Agronomical Research Institute) in Champenoux near Nancy, April 1, 2010. The INRA research unit, lead by research director Francis Martin, has sequenced the genome of the Perigord black truffle to better understand the symbiosis between trees and fungus, including truffles, to ameliorate it's natural growth. REUTERS/Vincent Kessler (FRANCE - Tags: AGRICULTURE ENVIRONMENT FOOD SCI TECH)

GM1E63U1SH001 Visitors look through a glass as researchers work with gene sequencers inside a "Sequencing Lab" at the Beijing Genomics Institute in Shenzhen, southern China March 3, 2010. Some experts say the world is on the cusp of a "golden age" of genomics, when a look at the DNA code will reveal your risk of cancer, diabetes or heart disease, and predict which drugs will work for you. Yet the $3 billion international Human Genome Project, whose first phase was completed a decade ago, has not led to a single blockbuster diagnosis or product. Picture taken March 3, 2010. To match SPECIAL REPORT SCIENCE/GENOME REUTERS/Bobby Yip (CHINA - Tags: SCI TECH HEALTH BUSINESS)

GM1E63U1SGX01 Researchers work with gene sequencers inside a "Sequencing Lab" at the Beijing Genomics Institute in Shenzhen, southern China March 3, 2010. Some experts say the world is on the cusp of a "golden age" of genomics, when a look at the DNA code will reveal your risk of cancer, diabetes or heart disease, and predict which drugs will work for you. Yet the $3 billion international Human Genome Project, whose first phase was completed a decade ago, has not led to a single blockbuster diagnosis or product. Picture taken March 3, 2010. To match SPECIAL REPORT ENCE/GENOME REUTERS/Bobby Yip (CHINA - Tags: SCI TECH HEALTH BUSINESS)

GM1E63U1RNM01 A researcher injects DNA material onto a laboratory dish inside a "Sequencing Lab" at the Beijing Genomics Institute in Shenzhen, southern China March 3, 2010. Some experts say the world is on the cusp of a "golden age" of genomics, when a look at the DNA code will reveal your risk of cancer, diabetes or heart disease, and predict which drugs will work for you. Yet the $3 billion international Human Genome Project, whose first phase was completed a decade ago, has not led to a single blockbuster diagnosis or product. Picture taken March 3, 2010. To match SPECIAL REPORT SCIENCE/GENOME REUTERS/Bobby Yip (CHINA - Tags: SCI TECH HEALTH BUSINESS)

GM1E63U11YY01 Bio Technician Javier Quinones demonstrates the beginning of the sequencing procedure in the sequencing laboratory at the J. Craig Venter Institute in Rockville, Maryland, March 29, 2010. Some experts say the world is on the cusp of a "golden age" of genomics, when a look at the DNA code will reveal your risk of cancer, diabetes or heart disease, and predict which drugs will work for you. Yet the $3 billion international Human Genome Project, whose first phase was completed a decade ago, has not led to a single blockbuster diagnosis or product. To match Special Report SCIENCE/GENOME. REUTERS/Larry Downing (UNITED STATES - Tags: SCI TECH)

GM1E63U11G601 Bio Technician Jason Mitchell demonstrates pipetting in the sequencing laboratory at the J. Craig Venter Institute in Rockville, Maryland, March 29, 2010. Some experts say the world is on the cusp of a "golden age" of genomics, when a look at the DNA code will reveal your risk of cancer, diabetes or heart disease, and predict which drugs will work for you. Yet the $3 billion international Human Genome Project, whose first phase was completed a decade ago, has not led to a single blockbuster diagnosis or product. To match Special Report SCIENCE/GENOME. REUTERS/Larry Downing (UNITED STATES - Tags: SCI TECH)

GM1E63U11G401 Bio Technician demonstrates the loading of the high tech 454 Life Science sequencing machine in the sequencing laboratory at the J. Craig Venter Institute in Rockville, Maryland, March 29, 2010. Some experts say the world is on the cusp of a "golden age" of genomics, when a look at the DNA code will reveal your risk of cancer, diabetes or heart disease, and predict which drugs will work for you. Yet the $3 billion international Human Genome Project, whose first phase was completed a decade ago, has not led to a single blockbuster diagnosis or product. To match Special Report SCIENCE/GENOME. REUTERS/Larry Downing (UNITED STATES - Tags: SCI TECH)

GM1E63U11G301 Bio Technician Javier Quinones sits at a computer terminal in the sequencing laboratory at the J. Craig Venter Institute in Rockville, Maryland, March 29, 2010. Some experts say the world is on the cusp of a "golden age" of genomics, when a look at the DNA code will reveal your risk of cancer, diabetes or heart disease, and predict which drugs will work for you. Yet the $3 billion international Human Genome Project, whose first phase was completed a decade ago, has not led to a single blockbuster diagnosis or product. To match Special Report SCIENCE/GENOME. REUTERS/Larry Downing (UNITED STATES - Tags: SCI TECH)

GM1E63U10PW01 Senior Manager for Production Sequencing Steven Ferriera sits next to a high tech Illumina clustering station genome analyzer (R) in the sequencing laboratory at the J. Craig Venter Institute in Rockville, Maryland, March 29, 2010. Some experts say the world is on the cusp of a "golden age" of genomics, when a look at the DNA code will reveal your risk of cancer, diabetes or heart disease, and predict which drugs will work for you. Yet the $3 billion international Human Genome Project, whose first phase was completed a decade ago, has not led to a single blockbuster diagnosis or product. To match Special Report SCIENCE/GENOME. REUTERS/Larry Downing (UNITED STATES - Tags: SCI TECH)

GM1E45V09BZ01 Geneticist Marjolein Kriek poses on top of a printout of her "DNA sequence map" at the Leid's Medical Centre in Leiden May 29, 2008. Kriek, 34, is only the fifth person to have their genetic information mapped for scientific study, and says it was high time women took part in mapping the human genome. The Dutch geneticist has become the first woman to have her DNA mapped -- a process that is rapidly becoming faster and cheaper as equipment and techniques improve. REUTERS/Jerry Lampen (NETHERLANDS)

GM1E45V08NN01 Geneticist Marjolein Kriek poses on top of a printout of her "DNA sequence map" at the Leid's Medical Centre in Leiden May 29, 2008. Kriek, 34, is only the fifth person to have their genetic information mapped for scientific study, and says it was high time women took part in mapping the human genome. The Dutch geneticist has become the first woman to have her DNA mapped -- a process that is rapidly becoming faster and cheaper as equipment and techniques improve. REUTERS/Jerry Lampen (NETHERLANDS)

GM1DWKITAYAA James D. Watson, co-discoverer of the DNA helix and father of the Human Genome Project, speaks at the Baylor College of Medicine's Human Genome Sequencing Center in Houston in this May 31, 2007 file photo. A prominent New York scientific laboratory suspended Nobel Prize-winning DNA authority Dr. James Watson on October 18, 2007 night over racially insensitive comments he was quoted as making in an interview earlier in the week. REUTERS/Richard Carson/Files (UNITED STATES)

GM1DWKITAQAA Dr. James Watson, co-discoverer of the DNA helix and father of the Human Genome Project, became the first human to receive the data encompassing his personal genome sequence at Baylor College of Medicine in Houston in this May 31, 2007 file photo. A prominent New York scientific laboratory suspended Nobel Prize-winning DNA authority Dr. James Watson on October 18, 2007 night over racially insensitive comments he was quoted as making in an interview earlier in the week. REUTERS/Richard Carson/Files (UNITED STATES)

GM1DVJQGDCAA Dr. James D. Watson (R), co-discoverer of the DNA helix and father of the Human Genome Project, stands inside the laboratory at the Baylor College of Medicine's Human Genome Sequencing Center in Houston May 31, 2007. Watson became the first human to receive the data encompassing his personal genome sequence after a $1 million two-month project that is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center. REUTERS/Richard Carson (UNITED STATES)

GM1DVJQDYHAA Researchers and medical students line up for an autograph from Dr. James D. Watson, co-discoverer of the DNA helix and father of the Human Genome Project, at the Baylor College of Medicine's Human Genome Sequencing Center in Houston May 31, 2007. Watson became the first human to receive the data encompassing his personal genome sequence after a $1 million two-month project that is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center. REUTERS/Richard Carson (UNITED STATES)

GM1DVJQCTMAA James D. Watson, co-discoverer of the DNA helix and father of the Human Genome Project, speaks at the Baylor College of Medicine's Human Genome Sequencing Center in Houston May 31, 2007. Watson became the first person to receive data encompassing his personal genome sequence after a two-month $1 million project that is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center. REUTERS/Richard Carson (UNITED STATES)

GM1DVJQBFGAA James D. Watson (L), co-discoverer of the DNA helix and father of the Human Genome Project, prepares to autograph his book for a researcher at the Baylor College of Medicine's Human Genome Sequencing Center in Houston May 31, 2007. Watson became the first person to receive data encompassing his personal genome sequence after a two-month $1 million project that is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center. REUTERS/Richard Carson (UNITED STATES)

GM1DVJQAXZAA James D. Watson, co-discoverer of the DNA helix and father of the Human Genome Project, speaks at the Baylor College of Medicine's Human Genome Sequencing Center in Houston May 31, 2007. Watson became the first person to receive data encompassing his personal genome sequence after a two-month $1 million project that is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center. REUTERS/Richard Carson (UNITED STATES)

GM1DVJQAEQAA James D. Watson, co-discoverer of the DNA helix and father of the Human Genome Project, stands inside a laboratory at the Baylor College of Medicine's Human Genome Sequencing Center in Houston May 31, 2007. Watson became the first person to receive data encompassing his personal genome sequence after a two-month $1 million project that is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center. REUTERS/Richard Carson (UNITED STATES)

GM1DVJPZFQAA James D. Watson, co-discoverer of the DNA helix and father of the Human Genome Project, autographs a book for a researcher at the Baylor College of Medicine's Human Genome Sequencing Center in Houston May 31, 2007. Watson became the first person to receive the data encompassing his personal genome sequence after a two-month $1 million project that is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center. REUTERS/Richard Carson (UNITED STATES)

GM1DVJPYLIAA Dr. James D. Watson, co-discoverer of the DNA helix and father of the Human Genome Project, became the first human to receive the data encompassing his personal genome sequence at Baylor College of Medicine in Houston May 31, 2007. The small hard drive he is holding contains about 20 gigabytes of data that is a result of a two-month $1 million project that is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center. REUTERS/Richard Carson (UNITED STATES)

PBEAHUONABA The Dalai Lama (L) is assisted by Whitehead Institute/MIT Center for Genome Research Director Eric Lander (R) as he prepares mouse DNA for sequencing with a syringe and pipet, September 13, 2003 during a visit to the center in Cambridge, Massachusetts. [The Tibetan Buddhist spiritual leader is participating in a two-day "Mind and Life" conference on science, spirituality and human biology at the Massachusetts Institute of Technology while in the Boston area.]

PBEAHUONAAZ The Dalai Lama (C) is assisted by Whitehead Institute/MIT Center for Genome Research scientist Yama Chopel (L) and Center Director Eric Lander (R) as he prepares mouse DNA for sequencing with a syringe and pipet, September 13, 2003 at the lab in Cambridge, Massachusetts. [The Tibetan Buddhist spiritual leader is participating in a two-day "Mind and Life" conference on science, spirituality and human biology at the Massachusetts Institute of Technology while in the Boston area.]

RP4DRIADGSAA The Dalai Lama examines mouse DNA in a test tube after helping prepareit for sequencing during a visit to the Whitehead Institute/MIT Centerfor Genome Research, September 13, 2003 in Cambridge, Massachusetts.The Tibetan Buddhist spiritual leader is participating in a two-day"Mind and Life" conference on science, spirituality and human biologyat the Massachusetts Institute of Technology while in the Boston area.REUTERS/Jim BourgJRB/HB

RP4DRHZUUCAA The Dalai Lama prepares mouse DNA for sequencing with a syringe andpipet, September 13, 2003 as he visits the Whitehead Institute/MITCenter for Genome Research in Cambridge, Massachusetts. The TibetanBuddhist spiritual leader is participating in a two-day "Mind and Life"conference on science, spirituality and human biology at theMassachusetts Institute of Technology while in the Boston area.REUTERS/Jim BourgJRB/HB

RP4DRHYVSZAA The Dalai Lama (C) is assisted by Whitehead Institute/MIT Center forGenome Research scientist Yama Chopel (L) and Center Director EricLander (R) as he prepares mouse DNA for sequencing with a syringe andpipet, September 13, 2003 at the lab in Cambridge, Massachusetts. TheTibetan Buddhist spiritual leader is participating in a two-day "Mindand Life" conference on science, spirituality and human biology at theMassachusetts Institute of Technology while in the Boston area.REUTERS/Jim BourgJRB/HB

RP4DRHYVSYAB The Dalai Lama (L) is assisted by Whitehead Institute/MIT Center forGenome Research Director Eric Lander (R) as he prepares mouse DNA forsequencing with a syringe and pipet, September 13, 2003 during a visitto the center in Cambridge, Massachusetts. The Tibetan Buddhistspiritual leader is participating in a two-day "Mind and Life"conference on science, spirituality and human biology at theMassachusetts Institute of Technology while in the Boston area.REUTERS/Jim BourgJRB/HB

RP4DRHYVFVAB The Dalai Lama (R) bends down to watch as technician Choe Dolma (C)explains a machine sequencing canine DNA during his visit to theWhitehead Institute/MIT Center for Genome Research September 13, 2003in Cambridge, Massachusetts. The Tibetan Buddhist spiritual leader isparticipating in a two-day conference on science, spirituality andhuman biology at the Massachusetts Institute of Technology while in theBoston area. REUTERS/Jim BourgJRB/GAC

PBEAHUKRWFM Australian Museum Director Professor Michael Archer looks at an 1866 Tasmanian Tiger embryo and skeleton in Sydney May 28, 2002 that scientists have used to successfully replicate some of the animals genes using DNA extracted from the specimen. Scientists say they hope to clone a Tasmanian Tiger in 10 years if they are successful in constructing large quantities of all the genes of the extinct animal and sequencing sections of the genome to create a genetic library of Tasmanian Tiger DNA. The animal, also known as a thylacine, was a dog-like carnivirous marsupial with stripes on its back that lived on the Australian island state of Tasmania before it was hunted down by farmers who blamed it for killing sheep. The last known tiger died in 1936.

RP3DRHZOHXAB Australian Museum Director Professor Michael Archer looks at an 1866Tasmanian Tiger embryo and skeleton in Sydney May 28, 2002 thatscientists have used to successfully replicate some of the animalsgenes using DNA extracted from the specimen. Scientists say they hopeto clone a Tasmanian Tiger in 10 years if they are successful inconstructing large quantities of all the genes of the extinct animaland sequencing sections of the genome to create a genetic library ofTasmanian Tiger DNA. The animal, also known as a thylacine, was adog-like carnivirous marsupial with stripes on its back that lived onthe Australian island state of Tasmania before it was hunted down byfarmers who blamed it for killing sheep. The last known tiger died in1936. REUTERS/David GrayDG/PB

RP3DRHZOHWAA Australian Museum Director Professor Michael Archer takes a close lookat an 1866 Tasmanian Tiger embryo in Sydney May 28, 2002 thatscientists have used to successfully replicate some of the animalsgenes using DNA extracted from the specimen. Scientists say they hopeto clone a Tasmanian Tiger in 10 years if they are successful inconstructing large quantities of all the genes of the extinct animaland sequencing sections of the genome to create a genetic library ofTasmanian Tiger DNA. The animal, also known as a thylacine, was adog-like carnivirous marsupial with stripes on its back that lived onthe Australian island state of Tasmania before it was hunted down byfarmers who blamed it for killing sheep. The last known tiger died in1936. REUTERS/David GrayDG/PB

RP3DRHZODIAA A security guard from the Australian Museum watches over an 1866Tasmanian Tiger embryo in Sydney May 28, 2002 that scientists have usedto successfully replicate some of the animals genes using DNA extractedfrom the specimen. Scientists say they hope to clone a Tasmanian Tigerin 10 years if they are successful in constructing large quantities ofall the genes of the extinct animal and sequencing sections of thegenome to create a genetic library of Tasmanian Tiger DNA. The animal,also known as a thylacine, was a dog-like carnivirous marsupial withstripes on its back that lived on the Australian island state ofTasmania before it was hunted down by farmers who blamed it for killingsheep. The last known tiger died in 1936. REUTERS/David GrayDG/PB

PBEAHUKXAFG - UNDATED PHOTO - Cepheid Corporation of Sunnyvale, California 'Smart Cycler TD System' is pictured in this undated publicity photograph. The highly portable system is capable of rapidly detecting DNA sequence specific to a biological organism such as the disease causing agent Anthrax with results in less than thirty minutes. Each Smart Cycler unit contains 16 I-CORE , (Intelligent Cooling/Heating Optical Reaction) modules that are capable of detecting up to 4 DNA targets in each sample in real time. The Smart Cycler unit is tethered to a laptop for use.

PBEAHUKXAFF - UNDATED PHOTO - Cepheid Corporation of Sunnyvale, California 'Smart Cycler TD System' is pictured in this undated publicity photograph. The highly portable system is capable of rapidly detecting DNA sequence specific to a biological organism such as the disease causing agent anthrax with results in less than thirty minutes. Each Smart Cycler unit contains 16 I-CORE , (Intelligent Cooling/Heating Optical Reaction) modules that are capable of detecting up to 4 DNA targets in each sample in real time. The Smart Cycler unit (L) is tethered to a laptop.

PBEAHULJSBB Dr. Francis Collins, Director of the National Institute of Health, announces the completion of the initial sequencing of the human genome June 26 in the East Room of the White House. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.

PBEAHULJSBA Craig Venter, President of the Celera Genomics Corporation, announces the completion of the initial sequencing of the human genome June 26 in the East Room of the White House. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.

RP2DRHZXAEAA U.S. President Bill Clinton announces the completion of the initial sequencing of the human genome June 26 in the East Room of the White House. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.WM/RCS

RP2DRHZWRIAA Dr. Francis Collins (R), Director of the National Institute of Health, answers questions during a June 26 press conference announcing the completion of the initial sequencing of the human genome with Greg Schuler (C), of the National Center for Biotechnology Information, and Dr. Craig Venter, President of the Celera Genomics Corporation. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.WM/CM/HB

RP2DRHZWKVAA Dr. Francis Collins, Director of the National Institute of Health, answers questions during a press conference announcing the completion of the initial sequencing of the human genome, June 26. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.WM/HB

RP2DRHZWFEAB U.S. President Bill Clinton applauds British Prime MInister Tony Blair via satellite as the two jointly announced the completion of the initial sequencing of the human genome, June 26. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.WM/CM

RP2DRHZWDRAA Dr. Francis Collins (R), Director of the National Institute of Health, shakes hands with Dr. Craig Venter, President of the Celera Genomics Corporation, as they announce the completion of the initial sequencing of the human genome June 26 in the East Room of the White House. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.WM/RCS

RP2DRHZWCTAB U.S. President applauds Dr. Craig Venter, President of the Celera Genomics Corporation (L) as they announce the completion of the initial sequencing of the human genome June 26 in the East Room of the White House. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.WM/RCS

RP2DRHZWBSAB U.S. President appears with Dr. Francis Collins (R), Director of the National Institute of Health, and Dr. Craig Venter (L) as they announce the completion of the initial sequencing of the human genome June 26 in the East Room of the White House. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.WM/RCS

RP2DRHZVTMAA Craig Venter, President of the Celera Genomics Corporation, announces the completion of the initial sequencing of the human genome June 26 in the East Room of the White House. Decoding the 3 billion chemical "letters" in human DNA is seen as one of history's great scientific milestones - the biological equivalent of the moon landing.WM/RCS

RP1DRILFUKAA Dr Nobuyoshi Shimizu stands by a model of DNA at Keio University in Tokyo December 1. A team of international scientists has deciphered the genetic code of a human chromosome in a scientific milestone that could herald new treatments for diseases ranging from heart disease to schizophrenia. Researchers from Britain, the United States and Japan including Prof Shimizu's scientist group have mapped the entire sequence of the protein-coding genes of chromosome 22, the second smallest of the 23 pairs of human chromosomes.TA/TS